LONDRES–(BUSINESS WIRE)–Icon Solutions y MongoDB han publicado hoy los resultados de una prueba de rendimiento conjunta que demuestra que el Icon Payments Framework (IPF), ejecutado en MongoDB Atlas, procesó 6000 transacciones de pago de extremo a extremo por segundo (alrededor de 430 000 operaciones de base de datos por segundo) con una latencia media de extremo a extremo de 0,51 segundos, y se recuperó de fallos tanto en la aplicación como en los nodos de la base de datos sin pérdida alguna
Month: September 2026
LONDRES–(BUSINESS WIRE)–Icon Solutions et MongoDB ont publié aujourd’hui les résultats d’un test de performance conjoint montrant que l’Icon Payments Framework (IPF), fonctionnant sur MongoDB Atlas, a traité 6 000 transactions de paiement de bout en bout par seconde (environ 430 000 opérations de base de données par seconde) avec une latence moyenne de bout en bout de 0,51 seconde, et s’est remis de pannes tant au niveau des nœuds d’application que des nœuds de base de données sans aucune per
LONDON–(BUSINESS WIRE)–Icon Solutions und MongoDB haben heute die Ergebnisse eines gemeinsamen Benchmarks veröffentlicht, der zeigt, dass das Icon Payments Framework (IPF), das auf MongoDB Atlas läuft, 6.000 End-to-End-Zahlungstransaktionen pro Sekunde (etwa 430.000 Datenbankoperationen pro Sekunde) mit einer mittleren End-to-End-Latenz von 0,51 Sekunden verarbeitete und sich sowohl von Anwendungs- als auch von Datenbankknotenausfällen ohne Datenverlust erholte. Das Volumen der Konto-zu-Konto
NEW YORK–(BUSINESS WIRE)–New Fortress Energy Inc. (NASDAQ: NFE) (the “Company”) today announced an update on the previously announced reverse stock split of the Company’s Class A common stock, par value $0.01 per share, at a ratio of 1-for-50 (the “Reverse Stock Split”). The Company expects trading of its Class A common stock to be halted prior to 8:00 p.m. Eastern Time on September 10, 2026. The Company’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasd
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) — Reconnaissance Energy Africa Ltd. (the “Company” or “ReconAfrica”) (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) (NSX: REC) is pleased to announce that it has completed its previously announced and upsized bought-deal public offering (the “Offering”) of 29,932,200 units of the Company (the “Units”) at a price of C$0.73 per Unit for aggregate gross proceeds to the Company of C$21,850,506, including the full exercise of the over-allotment option.
The Offering was led by Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and ATB Cormark Capital Markets (collectively, the “Underwriters”).
Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share (a “Warrant Share”) at an exercise price of C$0.93 until September 10, 2029. The Warrants are expected to commence trading on the TSX Venture Exchange (“TSXV”) under the symbol “RECO.WT.D” in the following week, subject to final TSXV acceptance.
The net proceeds from the Offering will be used for conducting an open-hole horizontal sidetrack and production testing program, targeting the primary reservoir in the Huttenberg formation and/or the secondary reservoir in the Elandshoek formation, and for general corporate purposes and working capital.
The Offering was completed by way of a prospectus supplement, to the Company’s short form base shelf prospectus dated April 13, 2026, with the securities regulatory authorities in each of the provinces of Canada (except Québec). Copies of the base shelf prospectus and any supplement thereto to be filed in connection with the Offering, are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
In connection with the Offering, the Company paid the Underwriters an aggregate cash commission of C$1,282,910.76 and issued to the Underwriters an aggregate of 1,757,412 broker warrants (the “Broker Warrants”). The Underwriters also received an aggregate advisory fee of C$15,000 and an aggregate of 6,000 advisory warrants on the same terms as the Broker Warrants. Each Broker Warrant entitles the holder thereof to acquire one Common Share at a price of C$0.73 until September 10, 2029.
This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.
About ReconAfrica
ReconAfrica is a Canadian oil and gas company engaged in the exploration of the Damara Fold Belt and Kavango Rift Basin in the Kalahari Desert of northeastern Namibia, southeastern Angola and northwestern Botswana, where the Company holds petroleum licences and access to ~13 million contiguous acres. The Company also operates the Ngulu block in the shallow waters offshore central Gabon covering 1,214 Km2 (equivalent to 54 Gulf of Mexico blocks) which is strategically located near producing oil fields and infrastructure. The Ngulu block includes the Loba oil field discovery and a large inventory of high impact prospects in the pre-salt and post-salt plays. In all aspects of its operations, ReconAfrica is committed to minimal disturbance of habitat in line with international standards and implementing environmental and social best practices in its project areas.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information contact:
Brian Reinsborough, President & Chief Executive Officer
Mark Friesen, Vice President, Investor Relations & Capital Markets
IR Inquiries Email: investors@reconafrica.com
Media Inquiries Email: media@reconafrica.com
Tel: +1-877-631-1160
Cautionary Note Regarding Forward-Looking Statements:
Certain statements contained in this press release constitute forward-looking information under applicable Canadian, United States and other applicable securities laws, rules and regulations, including, without limitation, statements with respect to the expected use of proceeds from the Offering, the trading of the Warrants on the TSXV and the Company’s commitment to minimal disturbances in line with international best standards and its implementation of environmental and social best practices in all of its project areas. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “potential”, “estimated”, “significant” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on ReconAfrica’s current beliefs or assumptions as to the outcome and timing of such future events. There can be no assurance that such statements will prove to be accurate, as the Company’s actual results and future events could differ materially from those anticipated in these forward-looking statements as a result of the factors discussed in the “Risk Factors” section in the Company’s annual information form (“AIF”) dated April 14, 2026, for the financial period ended December 31, 2025, available under the Company’s profile at www.sedarplus.ca. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to ReconAfrica. The forward-looking information contained in this release is made as of the date hereof and ReconAfrica undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
NEW YORK–(BUSINESS WIRE)–This New York Fashion Week, beauty meets fashion. Leading medical aesthetics brand, JECT, is partnering with Brazilian fashion brand, PatBO, for its New York Fashion Week runway show on Tuesday, September 15. As PatBO’s official skincare partner, JECT will support select models with pre-show skincare treatments and bring its signature approach to beauty backstage with skincare prep. Guests will also receive limited-edition JECT x PatBO fans during the show. On Thursda
Appointment strengthens feasibility study execution and advances ARR’s pathway to producing separated rare earth oxides in Wyoming
HIGHLIGHTS
- Dr. Sanja Miskovic appointed Chief Technical Advisor, joining ARR’s technical leadership team effective immediately
- Will guide flowsheet development, recovery optimisation and process scale-up activities supporting separated rare earth oxide production in Wyoming
- More than 20 years of minerals processing, beneficiation, extraction and critical materials experience
- Supports ARR’s strategy to establish a domestic U.S. mine-to-magnet supply chain
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — American Rare Earths Limited (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or “the Company”) is pleased to announce the appointment of Dr. Sanja Miskovic as Chief Technical Advisor, effective immediately.
TECHNICAL LEADERSHIP APPOINTMENT STRENGTHENS ARR’S PATH TO SEPARATED RARE EARTH OXIDES
Dr. Miskovic will focus on process and recovery optimization as part of the feasibility study for the Company’s flagship Halleck Creek Rare Earths Project in Wyoming, USA. In this role, she will guide flowsheet development, beneficiation and hydrometallurgical recovery, and scale up decisions that support the production of separated rare earth oxides at the planned Wyoming processing site.
TWO DECADES OF PROCESS ENGINEERING AND CRITICAL MINERALS EXPERIENCE
Dr. Miskovic is a minerals and process engineering expert with more than 20 years of experience spanning academic and industrial research and development. Her expertise includes the development, design, optimization, and scale up of technologies for mineral beneficiation, chemical extraction, pyrometallurgical and thermal processing, and critical materials recovery.
Her career has covered energy and water efficient mineral liberation and concentration, metal extraction, purification and refining, and the development of high efficiency process equipment and reactor technologies, with projects progressing from laboratory proof of concept through pilot scale validation and industrial implementation.
Dr. Miskovic received her Ph.D. in Minerals Engineering from Virginia Tech in 2011 and holds M.Sc. and B.Sc. degrees from the University of Novi Sad. She serves as Chief Technology Officer of Novex, ARR’s downstream metallization technology partner, and holds an academic appointment at the University of British Columbia’s Norman B. Keevil Institute of Mining Engineering.
ADVANCING THE MINE TO MAGNET STRATEGY
Dr. Miskovic’s appointment reinforces the technical bench advancing Halleck Creek from resource to production and links directly to ARR’s strategy of building a generational U.S. domestic mine to magnet supply chain. Optimizing recovery at the front end of the flowsheet supports the delivery of separated rare earth oxides that feed into metallization, alloying, and permanent magnet production within the United States.
“Sanja brings the technical depth and operating instinct we need as we move Halleck Creek through feasibility and toward construction. Her focus on recovery and process optimization directly supports our objective of producing separated rare earth oxides in Wyoming and feeding those oxides into a domestic metallization and magnet supply chain. Her appointment strengthens an already strong technical team and reflects the continued focus on finding the best talent to advance the Halleck Creek project towards execution.”
– Mark Wall, Chief Executive Officer, American Rare Earths
“Halleck Creek is one of the most important rare earth developments in the United States, and the opportunity to shape process design and recovery decisions during feasibility is a rare one. I look forward to working with the American Rare Earths team to advance a flowsheet that delivers separated rare earth oxides efficiently and reliably, and that supports the broader ambition of a fully integrated U.S. mine to magnet supply chain.”
– Dr. Sanja Miskovic, Chief Technical Officer, Novex LLC
This announcement has been authorized for release by the Board of American Rare Earths Limited.
INVESTOR CONTACT
| Investor Relations Nick Lissolo nlissolo@americanree.com www.americanree.com |
Stock Information ASX: ARR OTCQX: ARRNF ADR: AMRRY Media Contact: Additional Investor Relations US Contact: |
ABOUT AMERICAN RARE EARTHS LIMITED
American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) is a critical minerals company at the forefront of reshaping the U.S. rare earths industry. Through its wholly owned subsidiary, Wyoming Rare (USA) Inc. (“WRI”), the company is advancing the Halleck Creek Project in Wyoming, a world class rare earth deposit with the potential to secure America’s critical mineral independence for generations. Located on Wyoming State land, the Cowboy State Mine within Halleck Creek offers cost efficient open pit mining methods and benefits from streamlined permitting processes in this mining friendly state.
With plans for onsite mineral processing and separation facilities, Halleck Creek is strategically positioned to reduce U.S. reliance on imports, predominantly from China, while meeting the growing demand for rare earth elements essential to defense, advanced technologies, and economic security. As exploration progresses, the project’s untapped potential on both State and Federal lands further reinforces its significance as a cornerstone of U.S. supply chain security. In addition to its resource potential, American Rare Earths is committed to environmentally responsible mining practices and continues to collaborate with U.S. Government supported R&D programs to develop innovative extraction and processing technologies for rare earth elements. Further information is available at www.americanree.com.
NEW YORK–(BUSINESS WIRE)–As financial institutions face growing regulatory complexity, increasing data demands, and pressure to do more with fewer resources, Wolters Kluwer Financial & Corporate Compliance today announced significant enhancements to its Wiz® Suite, including the introduction of Performance Analytics Wiz®. The expanded platform helps banks and credit unions move beyond fragmented compliance processes by connecting data, workflows, analytics, and reporting into a centralize
Collaboration with NCI’s Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001
in new indications and combination regimens
IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration
LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, IMUNON and the NCI’s Cancer Therapy Evaluation Program (CTEP) who assumes regulatory sponsorship will support further clinical and non-clinical development of IMNN-001, the Company’s DNA-based IL-12 immunotherapy, under the NCI Experimental Therapeutics (NExT) Program managed by CTEP. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.
Under the agreement, NCI investigators will evaluate IMNN-001 in new solid tumor indications and combination regimens, building on clinical data from the Company’s ongoing ovarian cancer program. IMUNON will retain ownership of its background intellectual property and will retain ownership of new intellectual property solely generated by IMUNON under the collaboration, including the right to use the data generated under the collaboration for the research and development of IMNN-001. For IMUNON, the collaboration provides an opportunity to leverage the NCI resources for generating additional clinical data for IMNN-001 in new indications.
“We believe our CRADA with NCI’s CTEP will explore the broad potential of IMNN-001 and our TheraPlas® platform,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “This partnership allows us to efficiently explore new indications and combinations through the expertise of CTEP and the National Clinical Trials Network (NCTN) utilizing the centralized clinical trial infrastructure funded by NCI, while keeping our team fully focused on advancing our pivotal Phase 3 OVATION 3 study in frontline ovarian cancer as rapidly as possible.”
“The mechanistic rationale for IL-12 as a multipotent immune activator extends well beyond ovarian cancer, and this collaboration gives us a capital-efficient way to initiate additional clinical trials for IMNN-001 across diverse solid tumor types and indications,” said Douglas V. Faller, M.D., Ph.D., Executive Vice President and Chief Medical Officer of IMUNON.
IMNN-001 is currently being evaluated in IMUNON’s pivotal Phase 3 OVATION 3 trial in frontline advanced ovarian cancer, following encouraging results from the completed Phase 2 OVATION 2 study, in which IMNN-001 was associated with a 14.7-month increase in median overall survival compared to chemotherapy alone (45.1 vs. 30.4 months).
About IMNN-001 Immunotherapy
Designed using IMUNON’s proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity, acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive results from the completed Phase 2 OVATION 2 Study, which assessed IMNN-001 plus neoadjuvant and adjuvant chemotherapy compared to standard-of-care chemotherapy alone in 112 patients with newly diagnosed advanced ovarian cancer. IMNN-001 is now being evaluated in the Company’s pivotal Phase 3 OVATION 3 trial, enrolling patients with newly diagnosed advanced ovarian cancer at clinical sites across the U.S.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Investors Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com
TKM Grupp AS informed the stock exchange on 11 March 2026 of the completion of a transaction pursuant to which the Group’s subsidiary TKM Auto OÜ acquired 100% of the shares in Rohe Auto AS, 100% of the shares in SKO Motors OÜ and 100% of the shares in SKO Motors Kinnisvara OÜ. Rohe Auto AS and SKO Motors OÜ, acquired through the transaction, have been integrated into the Group’s car segment thereby strengthening the Group’s position in the Estonian automotive market. As a result of the transaction, the Group became the largest Škoda dealer in the Baltics.
Considering the corporate structure and business segments of TKM Grupp AS, it has been decided to merge SKO Motors Kinnisvara OÜ, the real estate company acquired as part of the above-mentioned transaction, with TKM Kinnisvara AS, which belongs to the Group’s real estate segment. To this end, a merger will be carried out whereby TKM Kinnisvara AS (as the acquiring company) will merge SKO Motors Kinnisvara OÜ (as the company being acquired) into itself.
Today, the parties signed the merger agreement in connection with the above-mentioned merger. The merger is expected to be registered in the Commercial Register in November 2026.
Raul Puusepp
Chairman of the Board
Phone: +372 731 5000
info@tkmgrupp.ee
